PRAMIPEXOLE TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

Mevcut itibaren:

SIVEM PHARMACEUTICALS ULC

ATC kodu:

N04BC05

INN (International Adı):

PRAMIPEXOLE

Doz:

0.5MG

Farmasötik formu:

TABLET

Kompozisyon:

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.5MG

Uygulama yolu:

ORAL

Paketteki üniteler:

100

Reçete türü:

Prescription

Terapötik alanı:

NONERGOT-DERIVATIVE DOPAMINE RECEPTOR AGONISTS

Ürün özeti:

Active ingredient group (AIG) number: 0152169002; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2018-01-09

Ürün özellikleri

_ _
_PRAMIPEXOLE Product Monograph _
_Page 1 of 59_
PRODUCT MONOGRAPH
PR
PRAMIPEXOLE
Pramipexole Dihydrochloride Tablets
0.25 mg, 0.5 mg, 1 mg & 1.5 mg
pramipexole dihydrochloride monohydrate
ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST
Sivem Pharmaceuticals ULC
4705 Dobrin Street
Saint-Laurent, Quebec, Canada
H4R 2P7
www.sivem.ca
Date of Revision:
November 10, 2021
Submission control No.: 257831
_ _
_PRAMIPEXOLE Product Monograph _
_Page 2 of 59_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
...................................................................................
5
ADVERSE REACTIONS
...................................................................................................
12
DRUG
INTERACTIONS....................................................................................................
21
DOSAGE AND ADMINISTRATION
...............................................................................
23
OVERDOSAGE
..................................................................................................................
26
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 27
STORAGE AND STABILITY
...........................................................................................
31
SPECIAL HANDLING INSTRUCTIONS
.........................................................................
31
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 31
PART II: SCIENTIFIC INFORMATION
..........................................................................
33
CLINICAL TRIALS
.................